Business
Curis, Inc. Announces 2021 Virtual Symposium: "VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond"
Experts in the field of immunotherapy will gather virtually on June 18, 2021 Symposium hosted by Randolph Noelle, Ph.D., and Padmanee Sharma, M.D., Ph.D.
About this update from Curis, Inc.
[{"type":"text","content":"Experts in the field of immunotherapy will gather virtually on June 18, 2021\n Symposium hosted by Randolph Noelle, Ph.D., and Padmanee Sharma, M.D., Ph.D.\n\n\nLEXINGTON, Mass., June 1, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the virtual symposium, \"VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond,\" taking place on June 18, 2021, 9:00-1:15 PM ET. \n\n \n \n \n \n \n \n\n \nLeaders in immunology across industry and academia will gather to discuss emerging checkpoint molecule, VISTA, including its function, the role it plays in several disease areas and current development programs. The event is organized by Curis and will be hosted by Randolph Noelle, Ph.D., Professor of Microbiology and Immunology, Department of Microbiology and Immunology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth; and Padmanee Sharma, M.D., Ph.D., Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas, MD Anderson Cancer Center. \n\"Over the last several years, there have been significant advancements from both academia and industry in the understanding and pursuit of VISTA as a target for immunotherapy, including the advancement of our own anti-VISTA antibody, CI-8993, into clinical trials,\" said James Dentzer, President and Chief Executive Officer of Curis. \"This symposium will bring together leading minds on the forefront of VISTA research and development to discuss the latest insights into this emerging checkpoint target and its potential applications in immuno-oncology, autoimmune diseases and other therapeutic areas.\" \nFree to attend, the event features agenda topics including: \nOverview of checkpoint therapy Introduction of VISTA VISTA regulation of the tumor microenvironment in human cancer Discovery of anti-VISTA antibodies VISTA counterreceptors Industry Panel: VISTA advances into clinical development To learn more about the symposium and register to attend please visit, https://bit.ly/3hBzIUj. \nAbout Curis, Inc.Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and p...